Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system

Elena L. Aronovich; Jason B. Bell; Shaukat A. Khan; Lalitha R. Belur; Roland Gunther; Brenda Koniar; Patricia A. Schachern; Josh B. Parker; Cathy S. Carlson; Chester B. Whitley; R. Scott McIvor; Pankaj Gupta; Perry B. Hackett

doi:10.1038/mt.2009.87

Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system

Elena L. Aronovich, Jason B. Bell, Shaukat A. Khan, Lalitha R. Belur, Roland Gunther, Brenda Koniar, Patricia A. Schachern, Josh B. Parker, Cathy S. Carlson, Chester B. Whitley, R. Scott McIvor, Pankaj Gupta, Perry B. Hackett

Research output: Contribution to journal › Article › peer-review

79 Scopus citations

Abstract

The Sleeping Beauty (SB) transposon system is a nonviral vector that directs transgene integration into vertebrate genomes. We hydrodynamically delivered SB transposon plasmids encoding human α-L-iduronidase (hIDUA) at two DNA doses, with and without an SB transposase gene, to NOD.129(B6)-Prkdc^scid IDUA^tm1Clk/J mice. In transposon-treated, nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice with mucopolysaccharidosis type I (MPS I), plasma IDUA persisted for 18 weeks at levels up to several hundred-fold wild-type (WT) activity, depending on DNA dose and gender. IDUA activity was present in all examined somatic organs, as well as in the brain, and correlated with both glycosaminoglycan (GAG) reduction in these organs and level of expression in the liver, the target of transposon delivery. IDUA activity was higher in the treated males than in females. In females, omission of transposase source resulted in significantly lower IDUA levels and incomplete GAG reduction in some organs, confirming the positive effect of transposition on long-term IDUA expression and correction of the disease. The SB transposon system proved efficacious in correcting several clinical manifestations of MPS I in mice, including thickening of the zygomatic arch, hepatomegaly, and accumulation of foamy macrophages in bone marrow and synovium, implying potential effectiveness of this approach in treatment of human MPS I.

Original language	English (US)
Pages (from-to)	1136-1144
Number of pages	9
Journal	Molecular Therapy
Volume	17
Issue number	7
DOIs	https://doi.org/10.1038/mt.2009.87
State	Published - 2009

Bibliographical note

Funding Information:
We thank Elizabeth A. Braunlin for testing cardiac function and Vladimir Tsuprun and Sebahattin Cureoglu for testing auditory function of mice; Walter C. Low, and Ilze Matise for helpful discussions; Dan Wolf, Kelly Podetz-Pedersen, and Mayra Garcia-Rivera for assistance with experiments, and the Masonic Cancer Center Comparative Pathology Shared Resource for assistance with pathology assessments (University of Minnesota). This project was supported by grant P01 HD32652 from the National Institutes of Health (NIH) and other funding from Beckman Center for Transposon Research at the University of Minnesota. R.S.M. and P.B.H. have equity in a small biotech company that receives funding from the NIH to explore the use of the SB Transposon System for gene therapy.

Access

10.1038/mt.2009.87

OpenUrl availability

Full text

Cite this

Aronovich, E. L., Bell, J. B., Khan, S. A., Belur, L. R., Gunther, R., Koniar, B., Schachern, P. A., Parker, J. B., Carlson, C. S., Whitley, C. B., McIvor, R. S., Gupta, P., & Hackett, P. B. (2009). Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system. Molecular Therapy, 17(7), 1136-1144. https://doi.org/10.1038/mt.2009.87

@article{f254e0082c4647e2ae7d58c1b3490c66,

title = "Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system",

abstract = "The Sleeping Beauty (SB) transposon system is a nonviral vector that directs transgene integration into vertebrate genomes. We hydrodynamically delivered SB transposon plasmids encoding human α-L-iduronidase (hIDUA) at two DNA doses, with and without an SB transposase gene, to NOD.129(B6)-Prkdcscid IDUAtm1Clk/J mice. In transposon-treated, nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice with mucopolysaccharidosis type I (MPS I), plasma IDUA persisted for 18 weeks at levels up to several hundred-fold wild-type (WT) activity, depending on DNA dose and gender. IDUA activity was present in all examined somatic organs, as well as in the brain, and correlated with both glycosaminoglycan (GAG) reduction in these organs and level of expression in the liver, the target of transposon delivery. IDUA activity was higher in the treated males than in females. In females, omission of transposase source resulted in significantly lower IDUA levels and incomplete GAG reduction in some organs, confirming the positive effect of transposition on long-term IDUA expression and correction of the disease. The SB transposon system proved efficacious in correcting several clinical manifestations of MPS I in mice, including thickening of the zygomatic arch, hepatomegaly, and accumulation of foamy macrophages in bone marrow and synovium, implying potential effectiveness of this approach in treatment of human MPS I.",

author = "Aronovich, {Elena L.} and Bell, {Jason B.} and Khan, {Shaukat A.} and Belur, {Lalitha R.} and Roland Gunther and Brenda Koniar and Schachern, {Patricia A.} and Parker, {Josh B.} and Carlson, {Cathy S.} and Whitley, {Chester B.} and McIvor, {R. Scott} and Pankaj Gupta and Hackett, {Perry B.}",

note = "Funding Information: We thank Elizabeth A. Braunlin for testing cardiac function and Vladimir Tsuprun and Sebahattin Cureoglu for testing auditory function of mice; Walter C. Low, and Ilze Matise for helpful discussions; Dan Wolf, Kelly Podetz-Pedersen, and Mayra Garcia-Rivera for assistance with experiments, and the Masonic Cancer Center Comparative Pathology Shared Resource for assistance with pathology assessments (University of Minnesota). This project was supported by grant P01 HD32652 from the National Institutes of Health (NIH) and other funding from Beckman Center for Transposon Research at the University of Minnesota. R.S.M. and P.B.H. have equity in a small biotech company that receives funding from the NIH to explore the use of the SB Transposon System for gene therapy.",

year = "2009",

doi = "10.1038/mt.2009.87",

language = "English (US)",

volume = "17",

pages = "1136--1144",

journal = "Molecular Therapy",

issn = "1525-0016",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system

AU - Aronovich, Elena L.

AU - Bell, Jason B.

AU - Khan, Shaukat A.

AU - Belur, Lalitha R.

AU - Gunther, Roland

AU - Koniar, Brenda

AU - Schachern, Patricia A.

AU - Parker, Josh B.

AU - Carlson, Cathy S.

AU - Whitley, Chester B.

AU - McIvor, R. Scott

AU - Gupta, Pankaj

AU - Hackett, Perry B.

N1 - Funding Information: We thank Elizabeth A. Braunlin for testing cardiac function and Vladimir Tsuprun and Sebahattin Cureoglu for testing auditory function of mice; Walter C. Low, and Ilze Matise for helpful discussions; Dan Wolf, Kelly Podetz-Pedersen, and Mayra Garcia-Rivera for assistance with experiments, and the Masonic Cancer Center Comparative Pathology Shared Resource for assistance with pathology assessments (University of Minnesota). This project was supported by grant P01 HD32652 from the National Institutes of Health (NIH) and other funding from Beckman Center for Transposon Research at the University of Minnesota. R.S.M. and P.B.H. have equity in a small biotech company that receives funding from the NIH to explore the use of the SB Transposon System for gene therapy.

PY - 2009

Y1 - 2009

N2 - The Sleeping Beauty (SB) transposon system is a nonviral vector that directs transgene integration into vertebrate genomes. We hydrodynamically delivered SB transposon plasmids encoding human α-L-iduronidase (hIDUA) at two DNA doses, with and without an SB transposase gene, to NOD.129(B6)-Prkdcscid IDUAtm1Clk/J mice. In transposon-treated, nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice with mucopolysaccharidosis type I (MPS I), plasma IDUA persisted for 18 weeks at levels up to several hundred-fold wild-type (WT) activity, depending on DNA dose and gender. IDUA activity was present in all examined somatic organs, as well as in the brain, and correlated with both glycosaminoglycan (GAG) reduction in these organs and level of expression in the liver, the target of transposon delivery. IDUA activity was higher in the treated males than in females. In females, omission of transposase source resulted in significantly lower IDUA levels and incomplete GAG reduction in some organs, confirming the positive effect of transposition on long-term IDUA expression and correction of the disease. The SB transposon system proved efficacious in correcting several clinical manifestations of MPS I in mice, including thickening of the zygomatic arch, hepatomegaly, and accumulation of foamy macrophages in bone marrow and synovium, implying potential effectiveness of this approach in treatment of human MPS I.

AB - The Sleeping Beauty (SB) transposon system is a nonviral vector that directs transgene integration into vertebrate genomes. We hydrodynamically delivered SB transposon plasmids encoding human α-L-iduronidase (hIDUA) at two DNA doses, with and without an SB transposase gene, to NOD.129(B6)-Prkdcscid IDUAtm1Clk/J mice. In transposon-treated, nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice with mucopolysaccharidosis type I (MPS I), plasma IDUA persisted for 18 weeks at levels up to several hundred-fold wild-type (WT) activity, depending on DNA dose and gender. IDUA activity was present in all examined somatic organs, as well as in the brain, and correlated with both glycosaminoglycan (GAG) reduction in these organs and level of expression in the liver, the target of transposon delivery. IDUA activity was higher in the treated males than in females. In females, omission of transposase source resulted in significantly lower IDUA levels and incomplete GAG reduction in some organs, confirming the positive effect of transposition on long-term IDUA expression and correction of the disease. The SB transposon system proved efficacious in correcting several clinical manifestations of MPS I in mice, including thickening of the zygomatic arch, hepatomegaly, and accumulation of foamy macrophages in bone marrow and synovium, implying potential effectiveness of this approach in treatment of human MPS I.

UR - http://www.scopus.com/inward/record.url?scp=67649844281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649844281&partnerID=8YFLogxK

U2 - 10.1038/mt.2009.87

DO - 10.1038/mt.2009.87

M3 - Article

C2 - 19384290

AN - SCOPUS:67649844281

SN - 1525-0016

VL - 17

SP - 1136

EP - 1144

JO - Molecular Therapy

JF - Molecular Therapy

IS - 7

ER -

Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system

Abstract

Bibliographical note

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this